Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
Author:
Affiliation:
1. Department of LeukemiaUniversity of Texas MD Anderson Cancer Center Houston Texas
2. Saint Louis Hospital Paris France
3. Department of Medicine, Princess Margaret Cancer CentreUniversity Health Network Toronto Ontario Canada
Funder
Bristol-Myers Squibb
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25342
Reference87 articles.
1. Complete cytogenetic and molecular responses to interferon-?-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
2. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
3. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
4. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
5. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Cited by 95 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The frequency of cardiovascular events caused by second-generation tyrosine kinase inhibitors may depend on the treatment intensity in patients with chronic myeloid leukemia;2024-08-18
2. Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety;Meditsinskiy sovet = Medical Council;2024-07-25
3. Long non-coding RNA PXN-AS1 promotes glutamine synthetase-mediated chronic myeloid leukemia BCR::ABL1-independent resistance to Imatinib via cell cycle signaling pathway;Cancer Cell International;2024-05-29
4. Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions;Current Hematologic Malignancy Reports;2024-02-23
5. Role of minimal residual disease assessment in multiple myeloma;Haematologica;2024-02-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3